UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of principal e ...

Financial Data and Key Metrics Changes - Net sales for Q1 2022 were $1.663 billion, an increase of 3.9% on a reported basis and 6.8% on a constant currency basis compared to Q1 2021 [12] - GAAP diluted earnings per share (EPS) decreased to $0.35 from $0.92 in Q1 2021, primarily due to unrealized investment losses and higher litigation-related charges [15] - Adjusted diluted EPS from continuing operations increased to $0.61 from $0.55 in Q1 2021, driven by higher sales and lower interest expenses [16] - Adjusted gross margin was 70.6%, lower than the previous year due to higher input costs, partially offset by better volume and mix [16] - Operating cash flows from continuing operations were $360 million, with free cash flow totaling $223 million for the quarter [17] Business Line Data and Key Metrics Changes - Global knees grew 11%, with U.S. knees up 11.7% and international knees up 10.1%, driven by strong commercial execution and recovery in knee procedures [14] - Global hips grew 4.5%, with U.S. hips up 3.3% and international hips up 5.6%, supported by recovery in primary and revision hip procedures [15] - The sports and extremities and trauma category increased by 1.8%, driven by strong performance in sports medicine and upper extremities [15] - The other category grew by 11.5% [15] Market Data and Key Metrics Changes - U.S. sales grew 5.8% due to a strong recovery as COVID cases subsided and elective procedures returned, with cancellation rates returning to pre-pandemic levels [12][13] - International sales grew 8.1%, driven by strong growth across Europe despite COVID surges in certain markets [14] Company Strategy and Development Direction - The company is focusing on innovation and has a strong new product pipeline, including AI-based solutions and robotics [7][8] - The company is committed to environmental, social, and governance (ESG) initiatives and has made significant progress in this area [9] - Active portfolio management is a key strategy, with the recent spin-off of ZimVie being part of this approach [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in 2022 growth due to stronger-than-expected COVID recovery, despite facing headwinds such as supply challenges and inflation [6][10] - The company raised and tightened its full-year guidance based on the positive trends observed in Q1 [11][19] - Management acknowledged ongoing staffing pressures in hospitals but noted improvements in procedure volumes [23][24] Other Important Information - The company has committed to key environmental standards and has enhanced its ESG reporting [9] - The company is actively managing its debt, having reduced it by about $650 million in Q1 [17] Q&A Session All Questions and Answers Question: What is the view on hospital-level staffing and CapEx spending headwinds? - Management acknowledged ongoing staffing pressures but noted improvements in procedure volumes and cancellation rates returning to pre-pandemic levels [23][24] Question: What are the trends in capital purchasing? - Management indicated that there is no shortage of capital and expressed optimism regarding capital allocation from hospitals [29] Question: How are inflationary pressures expected to impact margins? - Management expects inflationary pressures to be a 150 basis point headwind on margins, with some costs being capitalized into 2023 [34] Question: What is the outlook for China volumes and the impact of VBP? - Management noted that while China volumes have been negatively impacted by COVID surges, the overall impact was in line with expectations [38] Question: How is the company thinking about market share in the U.S.? - Management expressed confidence in market share growth, supported by a strong pipeline of new products and innovations [46][48] Question: What is the strategy for M&A post-spin? - Management emphasized active portfolio management and the importance of maintaining investment-grade ratings while exploring M&A opportunities [54][56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2021 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 13-4151777 | | --- | --- | | (State of Incorporation) | (IRS Employer | | | Identification No.) | | 345 East Main Street | 46580 | | Warsaw, Indiana | | (Address of principal executi ...

Zimmer Biomet Holdings Inc. (NYSE:ZBH) Q4 2021 Results Earnings Conference Call February 7, 2022 8:30 AM ET CompanyParticipants Keri Mattox - Senior Vice President Investor Relations Bryan Hanson - Chairman, President, and CEO Suky Upadhyay - EVP and CFO Conference Call Participants Josh Jennings - Cowen Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Steven Lichtman - Oppenheimer & Company Larry Biegelsen - Wells Fargo Matt Taylor - UBS Rick Wise - Stifel Chris Pasquale - Guggenheim Shagun Singh - RBC ...

Zimmer Biomet Holdings Inc. (NYSE:ZBH) Q3 2021 Earnings Conference Call November 4, 2021 8:30 AM ET Company Participants Bryan Hanson – Chairman, President, and CEO Keri Mattox – Senior Vice President Investor Relations Suky Upadhyay – EVP and CFO Conference Call Participants Ryan Zimmerman – BTIG Drew Ranieri – Morgan Stanley Amit Hazan – Goldman Sachs Joanne Wuensch – Citi Kyle Rose – Canaccord Sam Broido Kodatsky – Truist Mike Matson – Needham & Company Robbie Marcus – JPMorgan Matt Taylor – UBS Imron Z ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of princip ...

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q2 2021 Earnings Conference Call August 3, 2021 8:30 AM ET Company Participants Keri Mattox - Senior Vice President, Investor Relations and Chief Communications Officer Bryan Hanson - Chairman, President and CEO Suky Upadhyay - EVP & Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Vijay Kumar - Evercore ISI Anthony Petrone - Jefferies Steven Lichtman - Oppenheimer Larry Biegelsen - Wells Fargo Matt Miksic - Credit Suisse Rick Wise - Stifel M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of principal ex ...

Financial Data and Key Metrics Changes - Net sales in Q1 2021 were $1.847 billion, a reported increase of 3.6% and a constant currency increase of 0.8% compared to Q1 2020 [43] - GAAP diluted earnings per share were $0.94, significantly up from a loss of $2.46 in the previous year, while adjusted diluted earnings per share were $1.71, up about 60 basis points [53] - Operating cash flows were $247 million, and free cash flow totaled $137 million for the first quarter [55] Business Line Data and Key Metrics Changes - Global knee business declined by 5.2% year-over-year, impacted by COVID-19, but strong momentum was seen from Persona and ROSA Knee [49] - Global hip business increased by 0.3%, with growth in the Americas and Asia Pacific of 0.9% and 11.2% respectively [50] - Sports, extremity, and trauma segment grew by 7.2%, driven by strong growth in upper extremities and trauma [51] Market Data and Key Metrics Changes - Americas region saw a 1% increase, primarily due to a sharp rise in U.S. procedures in March [45] - EMEA region decreased by 10.3%, with all sub-markets in decline due to COVID-19 restrictions [45] - Asia Pacific grew by 15.5%, with solid year-over-year growth across major markets [46] Company Strategy and Development Direction - The company is focused on a transformation strategy that includes mission-centric M&A to enhance market growth without disrupting margins [29] - A planned spin-off of the spine and dental business is underway, aimed at creating two independent companies to enhance focus and strategy [32] - The company aims to evolve from a traditional implant provider to a leading med tech innovator, with over 70% of R&D spending directed towards the ZBEdge ecosystem [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovering from COVID-19, anticipating a significant tailwind from the backlog of deferred elective procedures [12][66] - The company expects to return to normalized market growth in key markets within the year, with guidance for 2021 indicating revenue growth of 14% to 17% [56] - Management remains confident in achieving mid-single digit growth and a 30% operating margin by the end of 2023 [34] Other Important Information - The company has made leadership changes, including appointing a Chief Transformation Officer to drive ongoing transformation efforts [14] - The ROSA Robotics platform continues to see strong market demand, with recent FDA approval for a partial knee application [19] - The company is preparing for the launch of Persona-IQ and ROSA hip later in the year, with positive initial feedback from surgeons [23] Q&A Session Summary Question: Backlog and Capacity - Management indicated that while the backlog is significant, the speed of addressing it will vary globally, with an estimated 12 to 18 months to work through the backlog [66][68] Question: Q2 Performance - Management expects sequential improvement in growth rates in Q2, with Asia Pacific expected to perform above Q2 2019 levels [77] Question: Persona-IQ Launch Timing - The company is awaiting FDA approval for Persona-IQ, with a limited launch expected in 2021 and a full launch in 2022 [80][82] Question: Cervical Disc Market Outlook - Management views the entry of competitors into the cervical disc market positively, believing it will expand the market and provide conversion opportunities [103] Question: Remote Patient Monitoring Reimbursement - While reimbursement for remote patient monitoring is desirable, management believes the data capture aspect will drive uptake regardless of reimbursement status [110]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of principal e ...